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1 Introduction 
 
 
The first kidney transplantation in Finland was done in 1964 when a mother donated 
one of her kidneys to her son. More than 5300 kidney transplants have been done in 
Finland since then. 350 of these kidneys are from living donors. Approximately 175 
kidney transplantations are performed annually. In the year 1980 1-year graft survival 
was only slightly more than 60%. As we learned how to prevent and manage hyperacute 
and acute rejection 1-year graft survival had risen to 94% by the year 2007 (1). The 
indication for kidney transplantation is end-stage renal disease. Diseases leading to this 
include diabetic nephropathy, glomerulonephritis, chronic pyelonephritis, obstructive 
nephropathy and haemolytic uraemic syndrome. 
 
Rejection is an immune response inducing injury and destruction in transplanted organs. 
Rejection is defined as hyperacute, acute and chronic, which is also called chronic 
allograft nephropathy (CAN) when kidney transplants are concerned. Hyperacute 
rejection occurs minutes to hours after transplantation. It is characterized by the 
development of cyanosis within the graft. Evidence of progressive cortical necrosis can 
be seen necessitating removal of the graft. Hyperacute rejection is caused by 
sensitization to alloantigen prior to the transplant. Acute rejection is seen days to weeks 
after transplantation and develops in a previously well functioning graft. Acute rejection 
occurs when transplantation has been performed despite of a positive T cell cross-
match. The recipient can also developed antibodies against donor HLA class 1 antigens 
after transplantation. Endothelial injury is the central feature of acute rejection (2). CAN 
is the primary reason for late allograft loss and returning to dialysis after a 
transplantation (3, 4). On of the most important features of CAN is the proliferation of 
smooth muscle cells (SMC) and their migration into the intima of blood vessels of the 
graft (5). This leads to luminal narrowing and decreased blood flow.  
 
Growth factors play an important role in the proliferation and migration of SMCs (6, 7, 
8). Through these actions they also have significant impact on the development of 
 2 
atherosclerosis. The growth factors considered in this study are platelet derived growth 
factor (PDGF), vascular endothelial growth factor (VEGF) and epidermal growth factor 
(EGF). They all belong to the receptor tyrosine kinases and inhibitors to them are used 
in clinical oncology. Inhibitors of receptor tyrosine kinases are potential new drugs in 
oncology. The first small molecular growth factor inhibitor approved for clinical use 
was Imatinib (GLIVEC®; Novartis) in 2001. The first indication for Imatinib was 
treatment of chronic myelogenous leukemia in blast crisis, in accelerated phase, or in 
progression of chronic phase after one interferon treatment. The indications for Imatinib 
have since then been widened to include gastrointestinal stromal tumors, among others 
(9). 
 
Sunitinib (SUTENT®; Pfizer) is a small molecule receptor tyrosine kinase inhibitor. Its 
inhibition concerns the class III / IV split kinase domain subgroup of receptor tyrosine 
kinases. This group contains platelet derived growth factor receptors (PDGFRs), 
vascular endothelial growth factor receptors (VEGFRs), the stem cell factor receptor (c-
KIT) and fibroblast growth factor receptor 1 (FGFR-1). Erlotinib (TARCEVA®; 
Roche) is an orally bioavailable receptor tyrosine kinase selectively inhibiting the 
epidermal growth factor receptor (EGFR). Both sunitinib and erlotinib are used in 
clinical oncology. 
 
Aorta denudation experiments are used as a model for accelerated atherosclerosis. In 
previous experiments our group has denudated the aorta of male Wistar rats (Scanbur, 
Sollentuna, Sweden) with balloon cathetry. Postoperatively the rats received either 
sunitinib or erlotinib treatment in different doses. After 14 days the area of neoitima of 
midaortic sections was analysed. In that in vivo study sunitinib and erlotinib decreased 
neotimal formation in a dose dependent manner. The immunohistochemistry revealed 
the  expression  of  PDGF-A  and  PDGF-B  in  the  neointimal  areas  of  the  control  rats  
treated with vehicle only. PDGF-B was expressed mainly on the luminal surface of the 
neointima. Sunitinib decreased the expression of these two growth factors (10).  
 
The aim of this study is to verify the results of our previous rat aorta denudation 
experiments. This time SMC will be studied in vitro. They are stimulated to proliferate 
with PDGF-B and then the effect of sunitinib and erlotinib on SMC proliferation will be 
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studied in three different doses. The hypothesis is that the effect of the medication on 
cell growth will show a similar dose dependent result as the one found in the denudation 
experiments. An important purpose of this study is also to develop a new protocol for 
SMC culturing in our laboratory. This will provide us with a valuable tool for further 
studies.  
 
 
 
2 Literature Review 
 
 
2.1  Chronic allograft nephropathy 
 
CAN is still the major problem in kidney transplantation. As 1-year graft survival is up 
to 94% due to excellent immunosuppressive therapy, CAN is an even increasing reason 
for late allograft loss (1). In a study with over 850 kidney transplant patients done by 
Ponticelli 11,2% of the patients lost the allograft due to CAN. In the same study, CAN 
was responsible for 49,2% of all allograft losses. The second most common cause was 
death 35,5%. This is to say that CAN is an even greater cause of allograft loss among 
the patient who survive (11). Histologically a mild form of CAN can be seen in 94,2% 
of adult patients one year after the transplantation (3). 
 
CAN can be seen from months to years after transplantation. Its clinical manifestations 
are gradual decrease in renal function accompanied by hypertension and hyperuricemia. 
(12, 13). CAN is characterized by tubular atrophy, interstitial fibrosis, glomerular 
changes and fibrous intimal thickening (4). The histological changes are seen early post-
transplant before alterations in renal function are evident (12). Vasculopathy is a 
prominent histological feature of CAN leading to vascular remodeling and concentric 
luminal narrowing due to intimal thickening caused by SMC proliferation and 
migration. This accelerated atherosclerosis of the blood vessels of the graft is believed 
to  be  one  major  factor  in  late  graft  loss  in  response  to  chronic  rejection  (5).  It  is  
hypothesized that acute rejection could cause the primary injury leading to CAN. Acute 
rejection causes induction of reparative mechanisms, resulting in fibrosis and 
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mesenchymal cell proliferation (14). Acute rejection episodes have proven to have a 
negative influence on graft survival (15). A part of this effect is probably due to 
subacute episodes, which cause no symptoms and therefore cannot be treated (16). 
Certain characteristics of the donor and recipient influence the risk of CAN (12). These 
include obesity, hypertension, hyperlipidemia and diabetes.  
 
 
2.2 Smooth muscle cells in atherosclerosis 
 
Many different cell types, including macrophages, lymphocytes, endothelial cells, and 
SMCs, are involved in the formation of atherosclerotic lesions. Damage to the 
endothelium or removal of it results in an increased SMC proliferation and migration 
(17). This is because the damaged endothelium produces less nitric oxide and attracts 
leucocytes. Nitric oxide increase SMC apoptosis and leucocytes secrete growth factors.  
 
Regions subjected to atherosclerotic plaque formation contain abundant SMCs whereas 
regions that are more resistant contain fewer. The medial layer contain the majority of 
the SMCs in the vessel walls but areas of the intima called intimal thickenings also 
contain large number of SMCs (18). Two types of thickenings have been identified: 
eccentric and diffuse. Eccentric intimal thickenings often involve up to half of the 
circumference of the arterial wall. They are found mainly in arterial branch points and 
areas of turbulent blood flow. Regions of eccentric thickening correlate with the later 
formation of atherosclerotic lesions. Diffuse thickenings occur throughout the vascular 
system and increase with age (18). 
 
The primary initiating event in atherosclerosis is the accumulation of low density 
lipoprotein (LDL) in the subendothelial matrix (19). The trapped LDL particles undergo 
modification, including oxidation, lipolysis, proteolysis and aggregation, and the 
modification leads to their contribution in inflammation and foam-cell formation (21). 
The majority of foam cells are thought to derive from macrophages. However also 
SMCs express LDL receptors and variety of other cholesterol uptake receptors and give 
rise to a significant number of lipid laden cells (20). 
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Atherosclerosis  is  a  form  of  chronic  inflammation  and  SMCs  contribute  to  the  
production of cytokines involved in this process. The extra cellular matrix accumulates 
during disease progression (20) and although endothelial cells and macrophages both 
contribute to extra cellular matrix production, SMCs are known to be the major 
producers of connective tissue both in the healthy and atherosclerotic vessels (22).  
 
 
2.3  Growth factors 
 
2.3.1 Platelet derived growth factor 
 
Ligands and receptors 
PDGF belongs to the receptor tyrosine kinases which exert their effect by catalyzing the 
transfer of the of the ? phosphate of ATP to hydroxyl groups of tyrosines on target 
proteins (23). Four different PDGF chains designated A through D have been identified, 
the PDGF-C and –D chains as late as in 2000 and 2001, respectively (24, 25). The A 
and B chains are ~100 amino acid residues long and show approximately 60% 
homology in amino acid sequence identity (6) while the C and D are 345 and 370 
residues long and share a 43% homology (26). Activated platelets secret PDGF -A, -B 
and  -C but  not  PDGF-D (27).  PDGF-A and  -B form both  homo-  and  heterodimerized  
functional polypeptide chains but PDGF-C and –D form only homodimers (26). All 
chains have to be proteolytically cleaved to be activated (28, 29). Human platelets 
whose ?-granules are the major storage site for PDGF contain AA, BB and AB dimers 
suggesting that the dimers are randomly assembled (30). PDGF dimerizes two receptors 
upon binding. ?-receptors bind all but PDGF-D chains and ?-receptors bind -B and -D 
chains (29).  
 
PDGF C and D are expressed in many organs. High levels are found in heart, pancreas, 
kidney and ovary. PDGF-D expression is generally lower than PDGF-C expression. In 
all  tissues  expressing  PDGF  -C  and  -D  the  classical  PDGF-A  and  PDGF-B  are  co-
expressed  (26).  In  another  recent  study  PDGF-C  and  PDGF-D  were  found  to  be  
expressed in macrophages, SMCs and endothelial cells in human atherosclerotic plaques 
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(31). This suggests that PDGF-C and PDGF-D, like PDGF-A and PDGF-B, play 
important roles in atherosclerosis. 
 
The receptor dimerization allows the cytoplasmic portions of the receptors to 
autophosphorylate each other on tyrosine recidues (32). It has also been shown that cell 
adhesion via integrin receptors leads to PDGFR activation (33). Receptor activation 
leads to the initiation of a number of different signaling pathways. 
Phosphatidylinositol3-kinase (PI3-kinase), phospholipase C (PLC)- ,  the  Src  family  of  
tyrosine kinases, the tyrosine phosphatase SHP-2 and GTPase activating protein (GAP) 
activating Ras are themselves enzymes phosphorylating and activating transcriptional 
factors (6). The strength of the signals is modulated by the simultaneous activation of 
stimulatory and inhibitory signals. The inhibition is conveyed by activation of tyrosine 
phosphatases, also stimulated by PDGF (34). 
 
Normal physiology 
PDGF is synthesized by many different cell types, as previously mentioned. The rate of 
synthesis is often increased in response to external stimuli, such as exposure to low 
oxygen saturation (35), thrombin (36) or stimulation by growth factors and cytokines 
(6). The expression of the different PDGF chains is independently regulated (37).  
 
Also the amount of receptors is dynamic and modulated by external stimuli. The cell’s 
response to the stimuli depends on the receptor type or types expressed on the cell (32). 
The classical target cells for PDGF, fibroblasts and SMCs, express both - and -
receptors, but generally higher levels of -receptors  (6).   The  expression  of  the  -
receptors on connective tissue cells is low but increases during inflammation (37). The 
stimulation of vascular SMCs with basic fibroblast growth factor selectively increases 
the expression of -receptors but not -receptors (38). 
 
PDGF is an important growth factor during development by means of paracrine 
function (6). It also bears an important role in maintaining the interstitial fluid pressure 
(39), probably through its ability to stimulate interactions between connective tissue 
cells and molecules of the extracellular matrix (6). 
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PDGF is important in wound healing and this also explains why it is an important factor 
in the development of atherosclerosis. As noted earlier, the quantity of -receptors is up-
regulated during inflammation. PDGF stimulates mitogenicity and chemotaxis of 
fibroblasts  and  SMCs  (6),  secretion  of  collagenase  by  fibroblasts  (40),  chemotaxis  of  
neutrophils and macrophages, growth factor production by macrophages and the 
production of several matrix molecules like fibronectin, collagen, proteoglycans, and 
hyaluronic acid (6). This leads to an increase in the formation of granulation tissue, rich 
in fibroblasts and glycosaminoglycans (41). PDGF is released by platelets, activated 
macrophages, thrombin-stimulated endothelial cells, SMCs of damaged arteries, 
activated fibroblasts, as well as by epidermal keratinocytes (6).  Reepitehelization and 
neovascularization also proceed with an increased rate, PDGF thus makes wound 
healing faster (41) while over activity of PDGF may be involved in the overhealing 
response of keloids (42). 
 
Pathophysiology  
PDGF is a major mitogen for SMCs and fibroblasts (6). SMCs make a big contribution 
to the formation of lipid laden cells, production of extra cellular matrix and cytokines 
(21, 22). This way PDGF has a central role in atherosclerosis. PDGF-A and smaller 
amounts of PDGF-B are found in cells in atherosclerotic lesions. The expression of 
PDGFR is also increased (43). SMCs in atherosclerosis often have altered gene 
expression patterns. PDGF-D stimulation can result in these kinds of alterations 
resulting in SMC accumulation. PDGF-D levels are up-regulated in endothelial cells 
exposed to hemodynamic forces (44). 
 
PDGF also not only stimulates cells to divide, but actively prevent them from dying (7). 
This is supported by the over expression of PDGF or PDGFR in various forms of 
cancer, such as glioblastoma and sarcoma (6). PDGF has been shown to have an 
angiogenic effect (45) and exert a feedback control effect on platelet aggregation. An 
increase in PDGF stimulation leads to decreased platelet aggregation (46).  
 
Clinical applications 
PDGF inhibitors are approved in the treatment of a number of malignancies. Imatinib is 
for example used in Philadelphia chromosome positive chronic myelogenous leukemia, 
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gastrointestinal stromal tumors and metastatic dermatofibrosarcoma protuberans (9). 
Sunitinib on the other hand is used in gastrointestinal stromal tumors and metastatic 
renal cell carcinoma (47). Nilotinib (TASIGNA®; Novartis) a newly approved PDGF 
inhibitor is indicated for chronic myelogenous leukemia when treatment with Imatinib 
has failed (48). 
 
 
2.3.2 Vascular endothelial growth factor 
  
Ligands and receptors 
There is a whole family of VEGFs but when using only VEGF it usually designates 
VEGF-A. Nine major splice forms of VEGF-A (from now on called only VEGF) have 
been identified in humans and are produced by alternative exon splicing. VEGF-165 is 
the major splice form due to its biological characteristics. The longest splice forms bind 
to the extra cellular matrix via the heparin-binding domain while the shorter splice 
forms lacking this domain are diffusible (49). The extra cellular matrix bound forms can 
be released by heparin and heparinase or by plasmin cleavage (50). A loss of the heparin 
binding domain results in reduced mitogenic activity (51). VEGF-121 and VEGF-165 
induce mitogenic and permeability-enhancing activity on endothelial cells, whereas the 
longer splice forms trigger only permeability- enhancing activity (50). Most cell types 
produce several VEGF splice forms simultaneously (52). 
 
VEGF binds to VEGFR-1, VEGFR-2 and to neuropilin1 (NP1), a co-receptor (53). All 
these three belong to the receptor tyrosine kinases. The binding sites on the VEGF are 
located at opposite ends of the molecule and can link two receptors to form homo- or 
heterodimers (52). VEGFR-1 expression is up-regulated by hypoxia and the function it 
mediates depends on the developmental stage and cell type. VEGFR-1 has been 
proposed to bind to VEGF and sequester it. This makes VEGF less available for binding 
to VEGFR-2. This way VEGFR-1 serves as a negative regulator to VEGFR-2 signaling 
(54). Another role of VEGFR-1 might be to regulate the paracrine release of tissue 
specific growth factors; VEGFR-1 stimulation has been found to augment the paracrine 
release of for example hepatocyte growth factor and IL-6 in liver sinusoidal cells (53, 
55).  An  alternative  splice  form  of  VEGFR-1,  called  sFlt-1,  has  been  shown  to  be  an  
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inhibitor of VEGF activity (54). VEGFR-2 has been accepted to be the major mediator 
of the angiogenic, mitogenic, growth inducing and permeability-enhancing effects of 
VEGF (53).  
VEGFR-1 and VEGFR-2 are expressed mainly on endothelial cells but additional cell 
types express one or both of the receptors (52). VEGFR-1 is for example found on 
hematopoetic stem cells, monocytes, vascular SMCs and renal mesangial cells whereas 
VEGFR-2 is found on circulating endothelial progenitor cells (56). In addition to the 
three receptors described above an additional VEGF-165 specific receptor has been 
found. Its expression is unusually large in several breast and prostate cancer cell lines 
(52). 
 
Normal physiology 
VEGF is a survival factor for endothelial cells both in vitro and in vivo and it promotes 
the growth of endothelial cells derived from arteries, veins and lymphatics. Furthermore 
mitogenic  effects  have  been  reported  on  retinal  pigment  cells,  Schwann  cells  and  
pancreatic duct cells among others (53). VEGF also modifies the spectrum of released 
growth factors from endothelial cells. The VEGF mediated increase of fibroblast growth 
factor  2  (FGF-2)  and  a  decrease  of  transforming  growth  factor  ?1  (TGF-?1)  leads  to  
SMC migration and proliferation (8). VEGFR activation also leads to activation of 
proteases required for the breakdown of the basement membrane and integrin 
expression, both required in angiogenesis, and initiation of cell migration (52). VEGF 
also promotes vasculogenesis (56).   
 
VEGF makes inflammatory reactions more severe by increasing the vascularity at the 
site of inflammation (57). VEGF induces an increase in hydraulic conductivity of 
isolated microvessels through increased calcium influx (58) as well as induces 
endothelial fenestrations in some vascular beds (59) hence VEGF is also called vascular 
permeability factor (VPF). VEGF may also be important for glomerular endothelial cell 
repair after injury (60).  
 
Inhibition of VEGF during development results in apoptotic changes in the vasculature, 
something not found during adulthood. It has been proposed that coverage by pericytes 
would be one of the factors making the vasculature independent of VEGF (53).  
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VEGF expression is stimulated by hypoxia and hypoglycemia (52), hormones such as 
estrogen (61), UV-B radiation and H2O2 (56) and growth factors such as TGF-?, TGF-?, 
EGF, keratinocyte growth factor, insulin like growth factor 1, FGF and PDGF (53). 
Hypoxia not only stimulates the induction of transcription but also stabilize the mRNA 
by protein binding (52). Antigen-, IL-2-, or hypoxia-activated T cells can produce 
VEGF and express VEGFR2. VEGF can in turn push the T-cells toward Th1 phenotype, 
which is associated with more cytotoxic T-cell activity (62). 
 
Pathophysiology 
Vascular changes due to up-regulation of VEGF are associated with cardiovascular 
disease, rheumatoid arthritis, diabetic retinopathy, delayed type hypersensitivity and 
asthma (57). Some of the previous studies point to that VEGF also promotes the 
progression of atherosclerosis (63). VEGF is expressed in aggregating macrophages in 
atherosclerotic lesions (64). Angiogenesis and growth of neointimal size in 
atherosclerotic plaques is thought to be mediated by VEGFR-2. VEGFR-1 mediates the 
migration of circulating monocytes into the vessel wall. This results in macrophage 
accumulation in the developing plaques (65).  
 
VEGF mRNA has been found to be expressed in the majority of human tumors. As 
tumors expand and the distance from the cells to the nearest blood vessel increases the 
tumorigenic cells respond to the hypoxia by stimulating VEGF production (53). 
 
Clinical applications 
Bevacizumab (AVASTIN®; Genentech/Roche) and ranibizumab (LUCENTIS®; 
Novartis) are humanized anti-VEGF monoclonal antibodies. Bevacizumab is used in 
combination with other antineoplastic drugs in treatment for metastatic colorectal 
carcinoma, metastatic breast cancer, advanced non-small cell lung cancer (NSCLC) and 
advanced renal cell carcinoma (66). The inhibition of VEGF function may also 
attenuate the tumour’s means to metastasize, possibly because the tumour cells come 
into contact with a lesser concentration of blood vessels (52). Ranibizumab is indicated 
for neovascular age-related macular degeneration (67). 
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2.3.3 Epidermal growth factor 
 
Ligands and receptors 
EGF is a single-chain acidic polypeptide of 53 aminoacid residues containing three 
intramolecular disulfide bonds, which are required for the proper tertiary structure. EGF 
is found in most bodily fluids, especially in milk (68). Early studies with EGF in the 
intact animal demonstrated its stimulatory effect on epidermal proliferation and 
inhibitory effect on gastric acid secretion (69).  
 
Epidermal growth factor receptor (EGFR, also known as HER- 1 or ErbB1) belongs to 
the class of membrane bound tyrosine kinases. Its basolateral location in the epithelium 
makes it a mediator of signals between mesenchyme and epithelium. EGFR is expressed 
in cells of mesodermal and ectodermal origin (70). The epidermal growth factor 
receptor family (ErbB family) consists of the receptors ErbB 1 through to 4 and are also 
called type 1 receptor tyrosine kinases. Ligand binding with the EGFR results in 
dimerization of the receptor at the cell surface (71), followed by internalization of the 
dimerized receptor after which the cytoplasmic tyrosine kinase domain is subjected to 
autophosphorylation (72).  
 
The EGFR is directly activated by EGF, TGF?, heparin-binding EGF, amphiregulin, 
betacellulin and epiregulin. The receptor is also activated by other factors, including 
membrane depolarizing agents, agonists for G-protein-coupled receptors, cytokine 
receptors such as prolactin and growth hormone and adhesion receptors, for example 
integrins. Also environmental stress factors such as ultraviolet irradiation, ?-irradiation, 
oxidizing agents, heat shock and hyperosmotic shock activate EGFR (73).  
 
Normal physiology 
The autophosphorylated EGF tyrosine kinase residues serve as binding sites for the 
recruitment of signal transducers and activators of intracellular substrates. These include 
PI3 -kinase, Ras mitogen-activated protein kinase cascades (74) and phospholipase C? 
(PLC?). These pathways regulate multiple biologic processes such as gene expression, 
cellular proliferation, division, differentiation, migration, angiogenesis and inhibition of 
apoptosis (72, 70). PI3 –kinase  promote  cell  survival  and  Ras  is  associated  with  cell  
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proliferation (74). Signaling through EGFR has been implicated in promoting 
proliferation and differentiation of the epithelial component of skin, lung, pancreas and 
the gastrointestinal tract (70). EGF is known to cause membrane ruffling formation due 
to extensive actin polymerization (75). Steroid hormones can augment the effect of 
EGFR signaling by activating the transcription of genes encoding for EGF ligands (70). 
 
Pathophysiology 
In normal skin EGFR expression is restricted to the basal layers whereas both the 
receptor and its ligand amphiregulin are expressed through the entire epidermal layer in 
psoriatic skin. EGFR is over expressed in the majority of solid tumors, including breast 
cancer, head-and-neck cancer, non-small-cell lung cancer (NSCLC), renal cancer, 
ovarian cancer, colon cancer and brain tumors. This promotes tumor growth, tumor cell 
motility,  adhesion  and  metastasis  (70,  72).  EGFR  activation  also  stimulates  VEGF  
production, which is the primary inducer in angiogenesis (72). The hepatitis B virus 
(HBV), Epstein-Barr virus (EBV) and human papilloma virus (HPV) alter the 
expression of the EGFR (70). 
 
Clinical applications 
At the moment there are two predominant classes of anti-EGFR agents used in clinical 
cancer treatment: small-molecule tyrosine kinase inhibitors competing with ATP for the 
binding to the intracellular catalytic domain of the receptor and monoclonal antibodies 
blocking the ligand binding extracellular domain preventing activation (76). Cetuximab 
(ERBITUX®;  Merck)  is  a  monoclonal  antibody.  It  can  be  used  in  some  forms  of  
EGFR-expressing metastatic colorectal cancers (77). Erlotinib is a receptor inhibitor and 
is used in treatment of metastatic pancreatic cancer and NSCLC (78).  
 
 
 
2.4 Sunitinib 
 
Sunitinib (SUTENT®; Pfizer) is a small molecule receptor tyrosine kinase inhibitor. It 
competitively inhibits VEGF dependent tyrosine phosphorylation of VEGFR and PDGF 
dependent phosphorylation of PDGFR? and signaling through c-KIT. Even signaling 
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mediated by the tyrosine kinase activity of FGFR-1 is inhibited but in a lower portion. 
(79) Sunitinib also inhibits fms-related tyrosine kinase (FLT3/FLK-2/Stk-2) signaling 
(80). All of these molecules belong to the class III / IV split kinase domain subgroup of 
receptor tyrosine kinases. The inhibition is highly selective for its substrates and no 
receptor tyrosine kinases outside this subgroup are inhibited (79, 81). Enzymatic 
activity of nonkinase enzymes and receptors are not affected by sunitinib (81). 
 
As hyperproliferation, migration, survival, differentiation, neoangiogenesis and invasion 
of tumors is enhanced by receptor tyrosine kinase signaling, sunitinib is used in cancer 
therapy. Clinical activity has been found in treatment for breast carcinomas, metastatic 
renal cell carcinomas and gastrointestinal stromal tumors (81). 
 
 
2.5 Erlotinib 
 
Erlotinib (TARCEVA®; Roche) is an orally bioavailable small molecule quinazoline 
derivative  that  selectively  inhibits  the  EGFR  tyrosine  kinase  (74).  It  prevents  
autophosphorylation by competing with adenosine triphosphate (ATP) for its binding 
site on the intracellular domain of EGFR (72). It is selective for EGFR and leads to the 
induction of apoptosis (82). It induces the disruption of mitochondrial function with loss 
of mitochondrial membrane potential and release of cytocrome c. The mechanism might 
be by facilitation of the formation of a megachannel in the outer mitochondrial 
membrane  (83).  Erlotinib  treatment  causes  cell  cycle  arrest  at  G1/S  phase  because  of  
accumulation of p27KIP1 protein in the nucleus of the cells. The accumulation is due to 
promotion of gene expression and decrease in degradation (74). 
 
The anticancer effects of erlotinib have been demonstrated in head-and-neck cancer, 
NSCLC, ovarian cancer and breast cancer (72). Erlotinib has been approved for 
treatment of locally advanced or metastatic NSCLC after failure of at least one 
chemotherapy  regimen.  It  has  also  been  approved  for  use  in  combination  with  
gemcitabine  as  first-line  treatment  of  patients  with  pancreatic  cancer  based  on  the  
improvement of overall and progression-free survival in a phase III trial (84). Erlotinib 
has also been shown to significantly reverse certain forms of multi drug resistance in 
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cancer cells by inhibiting the drug efflux and thus increasing the intracellular 
accumulation of the anticancer drugs (76) 
 
 
 
3 Material and methods 
 
 
3.1 Cell culture 
 
The rat coronary artery SMCs (provided by Dariusz Lesczynski; Finnish Centre for 
Radiation and Nuclear Safety, Helsinki, Finland) were cultured in a culturing chamber 
in 37°C and a CO2 concentration of approximately 5%. The cells were fed once every 
24 hour with a media containing DMEM (GibCo) with 10% fetal bovine serum (FBS), 
1% glutamine (GibCo), 2,5% penicillin and streptomycin (GibCo). The cells were split 
approximately once a week or when microscopic viewing showed a lack of space for the 
cells on the ground of the bottle.   
 
 
3.2 Study design 
 
At the beginning of the studies the cells were detached from the culturing bottle with 
trypsin/EDTA after which they were counted using a Burker counting chamber and 
appropriate equation. 550 cells were pipetted onto a 96-well breeding ground. The cells 
were allowed to attach to the ground in a FBS containing media for 24h after which the 
media was changed to a media lacking FBS and the cells were left in serum starvation 
for 72h. N = 6 for sunitinib experiments and n = 5 for erlotinib experiments. 
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3.3 Drug administration 
 
After  72h  of  starvation  the  cells  were  stimulated  to  proliferate  with  2ng/ml  of  PDGF  
and treated with either sunitinib or erlotinib raising the final concentrations in the wells 
to 0,05 ?M, 0,1 ?M and 0,2 ?M of sunitinb or 1 nM, 2 nM and 5 nM of erlotinib. The 
concentrations  were  based  on  information  about  IC50  values  available  on  the  EMEA  
website (78, 85). The sunitinib capsules and the erlotinib powder were dissolved in 
Dimethyl sulfoxide (DMSO, Sigma).  
 
 
3.4 Fixation and calculation 
 
24h after drug administration the cells were fixed to the breeding ground using a 2% 
paraformaldehyde (PFA) solution and dyed with Mayer. This made it possible to count 
the  cells  without  haste  and  to  later  return  to  the  wells  and  recount  them.  Four  
microscopic fields using a 10x magnification were counted from each chamber. 
 
 
3.5 Statistical analysis 
 
The results are expressed as mean ± standard error of mean. Probability (p) <0.05 was 
accepted as significant. The significance between groups was determined by parametric 
analysis of variance, SPSS® (Statistical Package for the Social Sciences). 
 
 
 
4 Results 
 
 
In order to analyze the results a value called proliferation index was created. The non-
stimulated  control  wells  were  given  the  proliferation  index  1,0.  When  the  other  wells  
had been counted they were all compared to the wells serving as control. These wells 
received proliferation indexes in their ratio to the control wells.  
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Sunitinib 
The data from sunitinib experiments (mean ± SD) is summarised in Table 1. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. 
 
 
 
 
We found that  PDGF stimulated  the  SMCs to  proliferate.  This  is  evident  since  PDGF 
stimulated cells 2,7 times compared to control cells. We also found that administration 
of sunitinib ameliorated cell proliferation. Already the lowest sunitinib concentration 
(0,05?M) inhibited the PDGF induced proliferation significantly. No significant 
difference was detected in proliferation between the lowest sunitinib dose treated cells 
and the non-stimulated control cells. Increasing the sunitinib dose decreased the  
proliferation even further although no significant difference was seen between the 
sunitinib doses. This is graphically illustrated in Figure 1.  
 
Wells Proliferation index SD 
Control 1 0 
PDGF 2,7 0,9 
Sunitinib 0,05uM 1,3 0,6 
Sunitinib 0,1 uM 1,0 0,3 
Sunitinib 0,2 uM 0,9 0,3 
 17 
0
0,5
1
1,5
2
2,5
3
3,5
4
Control PDGF Sunitinib 0,05uM Sunitinib 0,1 uM Sunitinib 0,2 uM
Proliferation index
 
Figure 1. The results of sunitinib administration on PDGF induced SMC proliferation.  
*  are significant (p<0,0001) compared to PDGF induced control cells.  
 
 
 
 
Erlotinib 
The data from the erlotinib experiments (mean ± SD) is summarised in Table 2.  
 
 
 
 
 
 
 
 
 
 
Table 2. 
Wells Proliferation index SD 
Control 1 0 
PDGF 2,1 0,6 
Erlotinib 1nM 0,8 0,3 
Erlotinib 2nM 0,5 0,2 
Erlotinib 5nM 0,8 0,5 
* 
 
* 
* 
* * 
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Very similar results were detected with erlotinib as with sunitinib. The administration of 
erlotinib also inhibited PDGF induced proliferation of SMCs. Erlotinib decreased the 
proliferation ratio to values under the non-stimulated control cells already with the 
lowest concentration (1nM). Increasing the dose led to a slight increase in inhibition but 
the difference was not significant. The difference between the cells treated with the 
lowest erlotinib concentration and the control was not significant. The results are 
illustrated in Figure 2.  
 
 
 
 
Figure 2. 
 
 
 
 
 
 
 
 
 
Figure 2. The results of erlotinib administration on PDGF induced SMC proliferation.  
* are significant (p<0,0001) compared to PDGF induced control cells.  
 
 
 
 
5  Discussion 
 
CAN is still the major problem in kidney transplantation. One of the central features of 
CAN is luminal narrowing in the vasculature of the graft. The formed neointima 
contains abundant SMCs (5). If the SMC proliferation and migration could be 
prevented, it would hopefully result in a better long-term graft outcome.  
0
0,5
1
1,5
2
2,5
3
Control PDGF Erlotinib 1nM Erlotinib 2nM Erlotinib 5nM
Proliferation index
* 
* 
* 
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In this study the aim was to investigate if the tyrosine kinase receptor inhibitors 
sunitinib and erlotinib would decrease the proliferation of SMCs in vitro. The results are 
unequivocal; both sunitinib and erlotinib prevent SMC proliferation. Sunitinib inhibits 
proliferation in a dose dependent matter. Already the lowest concentration decreases the 
proliferation to the level of controls. When increasing the sunitinib dose even further 
inhibition is seen although no statistical difference is seen between the different doses. 
Similar results are seen with erlotinib. Also erlotinib inhibited the proliferation to the 
level of controls with the lowest does used. No further inhibition is achieved with higher 
concentration.   
 
Our results concerning sunitinib are consistent with our previous experiments. Sunitinib 
ameliorates the neointima formation after arterial endothelial injury. This is through a 
combined inhibition of PDGF and VEGF signaling (10). The role of PDGF in initiating 
atherosclerosis is clear but the role of VEGF is still uncertain. VEGF seems to both 
cause plaque progression (63) and inhibit restenosis (86). In that study we demonstrate 
that the combined PDGF and VEGF-inhibition with sunitinib monotherapy prevented 
neointima formation almost completely. This indicates that PDGF has a bigger role in 
restenosis formation than VEGF has in preventing restenosis. Based on that data it 
seems that the inhibition of VEGF signaling with sunitinib still decreased neointima 
formation (87).  
 
Sunitinib selectively inhibits VEGF-dependent endothelial cell proliferation, vascular 
sprouting and tube formation at IC50 values between 4-55 nM (85). However, much 
higher IC50 values ranging from 0,1?M to 0,25?M have been needed to inhibit 
signaling through other growth factor receptors. We used the following sunitinib 
concentrations: 0,05 ?M, 0,1 ?M and 0,2 ?M, suggesting that in our study the inhibitory 
effect of sunitinib was also due to inhibition of other growth factors than VEGF.   
 
The  results  from  these  sunitinib  proliferation  studies  are  also  consistent  with  other  
results concerning PDGF/VEGF tyrosine kinase inhibition. Imatinib, another receptor 
tyrosine kinase inhibitor, inhibits signaling through PDGF, c-KIT and bcr-Abl 
receptors. It has been shown to prevent SMC proliferation in vitro (90, 91) and in vivo 
(92). Inhibition of SMC proliferation is probably due to its PDGFR inhibition. PTK787, 
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also receptor tyrosine kinase inhibitor, inhibits both PDGF and VEGF receptors and has 
been shown to partially inhibit PDGF induced SMC proliferation (91).  
 
In recent studies done in our laboratory erlotinib has had a dose dependent influence on 
the formation of neointima in denuded rat aortas (88). Results from the present study 
suggest  that  this  neointima  formation,  at  least  to  some  extent,  is  due  to  SMC  
proliferation and migration. Our findings are also consistent with the results found in an 
experimental pulmonary hypertension model. In that study EGFR blockers led to 
apoptosis of abnormally proliferated SMCs. This led to reversal of progressive vascular  
remodelling (89). If erlotinib could prevent the vascular remodelling in the graft, we 
would have a very potent drug against CAN. 
 
The IC50 value for erlotinib’s inhibition of EGFR signaling has been 2nM in previous 
in vitro studies (78). We used concentrations equal to the IC50 values (1 nM, 2 nM and 
5 nM of erlotinib) indicating that the inhibition was due to selective EGF inhibition. 
 
There are less studies concerning EGF in vascular biology. Genistein conjugated to 
EGF inhibits SMC migration in vitro and decreases the formation of neointima after 
vascular injury (93). Genistein inhibits the activities of tyrosine-specific protein kinases. 
In  this  case  inhibition  of  EGF  activity  was  due  to  competiton  with  ATP  and  the  
formation of nonproductive enzyme-substrate complexes (94). EGF binding sites are 
up-regulated in the neointima after balloon injury to the vasculature. They are 
concentrated to the cell layers closest to the lumen. This is also the site where the most 
sustained proliferative activity occurs (95). This confirms the role of EGF in SMC 
proliferation. 
 
In conclusion we state that sunitinib and erlotinib inhibit SMC proliferation in vitro. 
Inhibition of SMC proliferation could be a potential intervention site to inhibit the 
accelerated atherosclerosis seen in dysfunctioning kidney transplants. 
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